The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey

Shaimaa El-Ashwah, Jon Salmanton-García*, Yavuz M. Bilgin, Federico Itri, Pavel Žák, Barbora Weinbergerová, Luisa Verga, Ali S. Omrani, Maria Gomes da Silva, Tomáš Szotkowski, Monia Marchetti, Caterina Buquicchio, Marcio Nucci, Martin Schönlein, Francesca Farina, Caroline Besson, Lucia Prezioso, Summiya Nizamuddin, Julio Dávila-Valls, Sonia Martín-PérezValentina Bonuomo, Jaap Van Doesum, Maria Chiara Tisi, Francesco Passamonti, Gustavo Adolfo Méndez, Stef Meers, Johan Maertens, Alberto López-García, Andreas Glenthøj, Matteo Bonnani, Ikhwan Rinaldi, Irati Ormazabal-Vélez, Jorge Labrador, Austin Kulasekararaj, Ildefonso Espigado, Fatih Demirkan, Nick De Jonge, Graham P. Collins, Maria Calbacho, Ola Blennow, Murtadha Al-Khabori, Tatjana Adžić-Vukičević, Elena Arellano, Bojana Mišković, Miloš Mladenović, Anna Nordlander, Zdeněk Ráčil, Emanuele Ammatuna, Raul Cordoba, Ditte Stampe Hersby, Stefanie Gräfe, Ziad Emarah, Michaela Hanakova, Maria Vittoria Sacchi, Marriyam Ijaz, Laman Rahimli, Raquel Nunes Rodrigues, Giovanni Paolo Maria Zambrotta, Francesco Marchesi, Oliver A. Cornely, Livio Pagano

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    4 Citations (Scopus)
    42 Downloads (Pure)

    Abstract

    Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.

    Original languageEnglish
    Pages (from-to)199-208
    Number of pages10
    JournalLeukemia and Lymphoma
    Volume65
    Issue number2
    Early online date24-Jan-2024
    DOIs
    Publication statusPublished - 2024

    Keywords

    • Chronic myeloid leukemia
    • COVID-19
    • neoplasia
    • SARS-CoV-2
    • tirosine kinase inhibitor
    • vaccines

    Fingerprint

    Dive into the research topics of 'The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey'. Together they form a unique fingerprint.

    Cite this